Ordering Recommendation

May be useful when evaluating for systemic sclerosis or connective tissue disease associated with overlapping features of systemic sclerosis and/or myositis.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Serum separator tube.

Specimen Preparation

Transfer 1 mL serum to an ARUP standard transport tube. (Min: 0.3 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma. Contaminated, hemolyzed, or severely lipemic specimens.

Remarks
Stability

After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles).

Methodology

Qualitative Immunoblot

Performed

Tue, Thu, Sat

Reported

1-4 days

Reference Interval

Negative

Interpretive Data

The presence of PM/Scl-100 IgG antibody along with a positive ANA IFA nucleolar pattern is associated with connective tissue diseases such as polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc), and polymyositis/systemic sclerosis overlap syndrome. The clinical relevance of PM/Scl-100 IgG antibody with a negative ANA IFA nucleolar pattern is unknown. PM/Scl-100 is the main target epitope of the PM/Scl complex, although antibodies to other targets not detected by this assay may occur.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

86235

Components

Component Test Code* Component Chart Name LOINC
2003041 PM/Scl 100 Antibody, IgG 81732-0
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • ANA
  • Antinuclear Antibodies
  • Antinuclear Antibody
  • FANA
  • Fluorescent Antinuclear Antibodies
  • PM/Sci-100 IgG
  • PM/Scl-100
  • PM1 Antibody
  • Polymyositis
PM/Scl-100 Antibody, IgG by Immunoblot